Larotin, Fe S.
HRN: 22-25-85 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/29/2022
CEFTAZIDIME 1GM (VIAL)
11/29/2022
12/06/2022
IV
1g
Q8
Infected Breast Mass
Waiting Final Action
Indication: Empiric Type of Infection: BloodstreamSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes